vs
BNB PLUS CORP.（BNBX）与NEOGENOMICS INC（NEO）财务数据对比。点击上方公司名可切换其他公司
NEOGENOMICS INC的季度营收约是BNB PLUS CORP.的336.3倍（$190.2M vs $565.4K）。NEOGENOMICS INC同比增速更快（10.6% vs -52.8%）。过去两年NEOGENOMICS INC的营收复合增速更高（10.3% vs -22.0%）
新基因组公司（NeoGenomics）是美国一家经CLIA认证的临床实验室企业，提供药企服务与信息服务，专注于癌症基因诊断检测，旗下检测服务涵盖细胞遗传学、荧光原位杂交（FISH）、流式细胞术、免疫组化、解剖病理学及分子遗传学等多个领域，为肿瘤相关诊断提供专业支持。
BNBX vs NEO — 直观对比
营收规模更大
NEO
是对方的336.3倍
$565.4K
营收增速更快
NEO
高出63.3%
-52.8%
两年增速更快
NEO
近两年复合增速
-22.0%
损益表 — Q1 2026 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $565.4K | $190.2M |
| 净利润 | $-18.6M | — |
| 毛利率 | 55.8% | 43.8% |
| 营业利润率 | -3308.9% | -7.1% |
| 净利率 | -3288.6% | — |
| 营收同比 | -52.8% | 10.6% |
| 净利润同比 | -604.5% | — |
| 每股收益（稀释后） | $-2.08 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BNBXNEO
| Q4 25 | $565.4K | $190.2M | ||
| Q3 25 | $-21.1K | $187.8M | ||
| Q2 25 | $304.4K | $181.3M | ||
| Q1 25 | $983.4K | $168.0M | ||
| Q4 24 | $870.3K | $172.0M | ||
| Q3 24 | $-180.1K | $167.8M | ||
| Q2 24 | $472.8K | $164.5M | ||
| Q1 24 | $929.6K | $156.2M |
净利润BNBXNEO
| Q4 25 | $-18.6M | — | ||
| Q3 25 | $-5.3M | $-27.1M | ||
| Q2 25 | $-3.9M | $-45.1M | ||
| Q1 25 | $-3.3M | $-25.9M | ||
| Q4 24 | $-2.6M | — | ||
| Q3 24 | $-3.3M | $-17.7M | ||
| Q2 24 | $1.9M | $-18.6M | ||
| Q1 24 | $-4.5M | $-27.1M |
毛利率BNBXNEO
| Q4 25 | 55.8% | 43.8% | ||
| Q3 25 | 678.5% | 42.8% | ||
| Q2 25 | 1.7% | 42.6% | ||
| Q1 25 | 37.7% | 43.6% | ||
| Q4 24 | 69.7% | 44.9% | ||
| Q3 24 | — | 44.6% | ||
| Q2 24 | 51.3% | 44.1% | ||
| Q1 24 | 31.8% | 41.9% |
营业利润率BNBXNEO
| Q4 25 | -3308.9% | -7.1% | ||
| Q3 25 | 27991.7% | -14.4% | ||
| Q2 25 | -1213.6% | -26.3% | ||
| Q1 25 | -352.0% | -16.6% | ||
| Q4 24 | -342.2% | -10.7% | ||
| Q3 24 | 1641.0% | -12.6% | ||
| Q2 24 | -699.3% | -13.3% | ||
| Q1 24 | -389.2% | -19.6% |
净利率BNBXNEO
| Q4 25 | -3288.6% | — | ||
| Q3 25 | 24957.5% | -14.4% | ||
| Q2 25 | -1296.1% | -24.9% | ||
| Q1 25 | -336.0% | -15.4% | ||
| Q4 24 | -303.3% | — | ||
| Q3 24 | 1830.6% | -10.5% | ||
| Q2 24 | 397.6% | -11.3% | ||
| Q1 24 | -480.9% | -17.3% |
每股收益（稀释后）BNBXNEO
| Q4 25 | $-2.08 | — | ||
| Q3 25 | $332.65 | — | ||
| Q2 25 | $-34.00 | — | ||
| Q1 25 | $-15.35 | — | ||
| Q4 24 | $-417.53 | — | ||
| Q3 24 | $-2269.72 | — | ||
| Q2 24 | $1170.48 | — | ||
| Q1 24 | $-265.45 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $2.5M | $159.6M |
| 总债务越低越好 | — | $341.9M |
| 股东权益账面价值 | $18.8M | $836.6M |
| 总资产 | $20.7M | $1.4B |
| 负债/权益比越低杠杆越低 | — | 0.41× |
8季度趋势，按日历期对齐
现金及短期投资BNBXNEO
| Q4 25 | $2.5M | $159.6M | ||
| Q3 25 | $1.7M | $164.1M | ||
| Q2 25 | $4.7M | $154.7M | ||
| Q1 25 | $6.8M | $346.2M | ||
| Q4 24 | $9.3M | $367.0M | ||
| Q3 24 | $5.9M | $362.0M | ||
| Q2 24 | $10.4M | $355.1M | ||
| Q1 24 | $3.1M | $331.9M |
总债务BNBXNEO
| Q4 25 | — | $341.9M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $541.1M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益BNBXNEO
| Q4 25 | $18.8M | $836.6M | ||
| Q3 25 | $2.3M | $838.3M | ||
| Q2 25 | $7.3M | $854.0M | ||
| Q1 25 | $10.5M | $888.3M | ||
| Q4 24 | $12.8M | $902.3M | ||
| Q3 24 | $9.1M | $908.2M | ||
| Q2 24 | $12.4M | $915.9M | ||
| Q1 24 | $-48.1K | $923.4M |
总资产BNBXNEO
| Q4 25 | $20.7M | $1.4B | ||
| Q3 25 | $4.4M | $1.4B | ||
| Q2 25 | $9.9M | $1.4B | ||
| Q1 25 | $13.0M | $1.6B | ||
| Q4 24 | $16.0M | $1.6B | ||
| Q3 24 | $12.8M | $1.6B | ||
| Q2 24 | $16.7M | $1.6B | ||
| Q1 24 | $9.2M | $1.6B |
负债/权益比BNBXNEO
| Q4 25 | — | 0.41× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.60× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-5.5M | $1.3M |
| 自由现金流经营现金流 - 资本支出 | — | $-6.5M |
| 自由现金流率自由现金流/营收 | — | -3.4% |
| 资本支出强度资本支出/营收 | — | 4.1% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-21.8M |
8季度趋势，按日历期对齐
经营现金流BNBXNEO
| Q4 25 | $-5.5M | $1.3M | ||
| Q3 25 | $-3.1M | $8.9M | ||
| Q2 25 | $-2.6M | $20.3M | ||
| Q1 25 | $-3.2M | $-25.3M | ||
| Q4 24 | $-3.3M | $9.8M | ||
| Q3 24 | $-3.2M | $9.2M | ||
| Q2 24 | $-3.5M | $13.9M | ||
| Q1 24 | $-3.2M | $-25.9M |
自由现金流BNBXNEO
| Q4 25 | — | $-6.5M | ||
| Q3 25 | — | $570.0K | ||
| Q2 25 | $-2.6M | $14.0M | ||
| Q1 25 | $-3.4M | $-29.8M | ||
| Q4 24 | $-3.4M | $-1.8M | ||
| Q3 24 | — | $-1.6M | ||
| Q2 24 | $-3.5M | $814.0K | ||
| Q1 24 | — | $-31.5M |
自由现金流率BNBXNEO
| Q4 25 | — | -3.4% | ||
| Q3 25 | — | 0.3% | ||
| Q2 25 | -867.8% | 7.7% | ||
| Q1 25 | -342.7% | -17.8% | ||
| Q4 24 | -395.6% | -1.0% | ||
| Q3 24 | — | -0.9% | ||
| Q2 24 | -743.8% | 0.5% | ||
| Q1 24 | — | -20.2% |
资本支出强度BNBXNEO
| Q4 25 | — | 4.1% | ||
| Q3 25 | 0.0% | 4.4% | ||
| Q2 25 | 3.6% | 3.5% | ||
| Q1 25 | 18.8% | 2.7% | ||
| Q4 24 | 13.4% | 6.7% | ||
| Q3 24 | — | 6.4% | ||
| Q2 24 | 4.6% | 8.0% | ||
| Q1 24 | — | 3.6% |
现金转化率BNBXNEO
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -1.86× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BNBX
暂无分部数据
NEO
| Client Direct Billing | $133.4M | 70% |
| Commercial Insurance | $31.4M | 17% |
| Medicare And Other Governmental | $25.4M | 13% |
